TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23664773
Drug: IV ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV ketamine 0.5 mg/kg
Study: 21241489
Drug: Drotrecogin alfa
Normalized name: Drotrecogin Alfa
DrugBank: Drotrecogin alfa (DB00055)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drotrecogin alfa (activated) (DAA) at doses of 6, 12, 18, or 24 μg/kg/hour
Study: 21241489
Drug: Enoxaparin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin (1 mg/kg body weight twice daily)
Study: 12691509
Drug: Dianeal PD‐4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dianeal PD‐4 containing 0.1 g/L HA
Study: 1557981
Drug: Heparin surface
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin surface modified (HSM) intraocular lenses (IOLs)
Study: 23139373
Drug: Exenatide 10
Normalized name: EXENATIDE 10MCG/DOSE 2.4ML 60D PEN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exenatide 10 µg twice daily
Study: 10353581
Drug: Subcutaneous immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous immunotherapy
Study: 27770809
Drug: Active placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active placebo (benztropine mesylate, 1 mg)
Study: 31043657
Drug: Burdock tea
Normalized name: BURDOCK
Approvals — FDA: no, EMA: no, PMDA: no
Description: Burdock tea (1.5 g three times a day)
Study: 17290043
Drug: Infliximab (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infliximab (both doses)
Study: 10859289
Drug: L-5-methyltetrahydrofolate (MTHF)
Normalized name: L-5-methyltetrahydrofolate
DrugBank: Levomefolic acid (DB11256)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: L-5-methyltetrahydrofolate (MTHF) at 17 mg/d
Study: 8244149
Drug: Chemotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy with 5-epidoxorubicin emulsified in lipiodol
Study: 28961427
Drug: Diclofenac potassium
Normalized name: Diclofenac Potassium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diclofenac potassium (50 mg)
Study: 28251224
Drug: Paracetamol (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol (1 gram)
Study: 14678340
Drug: Duloxetine 40
Normalized name: duloxetine 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine 40 mg oral dose
Study: 15184278
Drug: Duloxetine (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine (various doses)
Study: 11822006
Drug: Omeprazole as
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Omeprazole as an adjunct to endoscopic intervention
Study: 8577182
Drug: D‐methamphetamine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: D‐methamphetamine (30 mg/70 kg) administered at 2130 h
Study: 8577182
Drug: D‐methamphetamine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: D‐methamphetamine (30 mg/70 kg)
Study: 39574
Drug: 0.50 mg
Normalized name: EVEROLIMUS 0.50 mg ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.50 mg MJ-9184-1
Study: 9137792
Drug: TBI +
Normalized name: TBI-223
DrugBank: TBI-223 (DB18911)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TBI + melphalan 140 mg/m2
Study: 9137792
Drug: melphalan 200
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: melphalan 200 mg/m2
Study: 23534323
Drug: Xylitol chewing
Normalized name: xylitol Chewing Gum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xylitol chewing gum treatment (3 times/day for 3 months)
Study: 15679251
Drug: Adjuvant treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant treatment strategies
Study: 15679251
Drug: Neoadjuvant or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant or adjuvant treatments
Study: 8874339
Drug: Vinorelbine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vinorelbine (30 mg/m2/week)
Study: 8874339
Drug: 5-FU/LV (425
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-FU/LV (425 mg/m2 and 20 mg/m2 for 5 consecutive days every 4 weeks)
Study: 25880227
Drug: GAME intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GAME intervention (goal-oriented activity-based, environmental enrichment therapy programme)
Study: 16443706
Drug: Salmeterol 50
Normalized name: FLUTICAS 100/SALMETEROL 50 INHL DISK 14
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmeterol 50 mug twice daily
Study: 8360932
Drug: Daily supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily supplementation with 14 vitamins and 12 minerals
Study: 3532585
Drug: 6-HRSZ2 (6-month
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6-HRSZ2 (6-month regimen, twice a week)
Study: 27160118
Drug: Group Remifentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group Remifentanil (remifentanil 2 µg/kg followed by propofol 2 mg/kg)
Study: 27160118
Drug: Group Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Group Propofol (propofol 2 mg/kg followed by remifentanil)
Study: 9869018
Drug: Lercanidipine 10
Normalized name: lercanidipine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lercanidipine 10 mg
Study: 24635387
Drug: Enalapril/Lercanidipine 20/10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril/Lercanidipine 20/10 mg combination
Study: 20668035
Drug: Intensive insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive insulin therapy (IIT) targeting normal-for-age fasting blood glucose levels
Study: 20668035
Drug: Insulin infusion
Normalized name: iLet Insulin Infusion 10-Pack Kit Inset
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin infusion only to prevent excessive hyperglycemia (Control)
Study: 18395305
Drug: Healive (new
Approvals — FDA: no, EMA: no, PMDA: no
Description: Healive (new preservative-free inactivated hepatitis A vaccine)
Study: 979068
Drug: Spirolactone (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spirolactone (400 mg, 200 mg, or 300 mg orally daily)
Study: 979068
Drug: Strophanthin (0.375
Approvals — FDA: no, EMA: no, PMDA: no
Description: Strophanthin (0.375 to 0.625 mg intravenously)
Study: 28625370
Drug: Apixaban (according
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apixaban (according to standard AF dosing)
Study: 28625370
Drug: Aspirin 81mg
Normalized name: ASPIRIN 81MG CAP
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin 81mg daily
Study: 24557584
Drug: PVI-directed fluid
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: PVI-directed fluid management (2 mL/kg/h crystalloid fluid infusion, rapid infusion of 250 mL colloid or crystalloid if PVI>13%)
Study: 24557584
Drug: Non PVI-directed
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non PVI-directed fluid management (4‐8 mL/kg/h crystalloid fluid infusion, quick fluid infusion if mean arterial BP<65 mmHg)
Study: 21736825
Drug: Salmon (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmon (2 × 120 g servings/week)
Study: 21736825
Drug: Salmon oil
Normalized name: Salmon Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmon oil capsules (2, 4, or 6 capsules/day)
Study: 16364555
Drug: 17.5 mg
Normalized name: acitretin 17.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 17.5 mg cortisol injection
Study: 8824965
Drug: Fluconazole (200-800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluconazole (200-800 mg daily, mostly 400 mg)
Study: 6429693
Drug: Imipramine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipramine administered orally (50 mg) 30 min after eating a standardized breakfast
Study: 31545017
Drug: Sequential peeling
Normalized name: orange peel extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential peeling and doxycycline PO100 mg BD for 1 month followed by 100 OD for 2 months
Study: 29678158
Drug: Dexmedetomidine (DEX)
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexmedetomidine (DEX) infusion at 0.5 μg/kg/h from induction of anaesthesia to extubation (Group D)
Study: 29678158
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline infusion (Group C)
Study: 21282185
Drug: Injection drug
Normalized name: Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection drug use
Study: 18310199
Drug: Concurrent administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Concurrent administration of live attenuated influenza vaccine with measles‐mumps‐rubella vaccine and varicella vaccine
Study: 18310199
Drug: Separate administration
Normalized name: Atractylis separate root
DrugBank: Atractylodes lancea root (DB14693)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Separate administration of live attenuated influenza vaccine
Study: 16699858
Drug: Continued lamivudine
Normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Continued lamivudine therapy (group A)
Study: 16699858
Drug: Discontinued lamivudine
Normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Discontinued lamivudine therapy (group B)
Study: 9033712
Drug: Oxiconazole cream
Normalized name: oxiconazole Topical Cream
DrugBank: Oxiconazole (DB00239)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxiconazole cream (1%)
Study: 9033712
Drug: Ketoconazole cream
Normalized name: Ketoconazole
DrugBank: Ketoconazole (DB01026)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketoconazole cream (2%)
Study: 6094103
Drug: Suloctidil (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suloctidil (200 mg 3-times daily)
Study: 23990709
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation of candesartan cilexetil 16 mg
Study: 20501356
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg calcium only
Study: 10693901
Drug: Standardized exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized exercise therapy
Study: 6315261
Drug: Norepinephrine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norepinephrine infusion after beta-blockade
Study: 6315261
Drug: Phentolamine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phentolamine infusion at the highest tolerated dose
Study: 28159505
Drug: Digital health
Normalized name: MENS HEALTH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digital health (DH) with sensor-enabled medicines for 4 or 12 weeks
Study: 28159505
Drug: Digital health
Normalized name: MENS HEALTH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digital health (DH) with sensor-enabled medicines
Study: 28209506
Drug: Steroid injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid injection plus splinting
Study: 25151027
Drug: GnRHa treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: GnRHa treatment for 6 months (Group 2A)
Study: 25151027
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (Group 1A)
Study: 19307374
Drug: Ampicillin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ampicillin (1 g intravenously every 6 hours)
Study: 19307374
Drug: Ampicillin plus
Normalized name: Ampicillin
DrugBank: Ampicillin (DB00415)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ampicillin plus oral P1A recombinant beta-lactamase (8.2 mg every 6 hours)
Study: 16540279
Drug: Exercise treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise treatment only (control group)
Study: 15228184
Drug: Intravenous adalimumab
Normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenous adalimumab (1 mg/kg)
Study: 8511505
Drug: Phenoxymethylpenicillin (PEN),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenoxymethylpenicillin (PEN), 2.4 million units twice daily for up to 14 weeks
Study: 3318454
Drug: Fenofibrate (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenofibrate (100 mg, three times daily)
Study: 20419161
Drug: Oral activated
Normalized name: activated charcoal Oral Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral activated charcoal (oAC)
Study: 20419161
Drug: Oral activated
Normalized name: activated charcoal Oral Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral activated charcoal (oAC) with artesunate (AS)
Study: 23313564
Drug: Duloxetine 60-120
Normalized name: duloxetine 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine 60-120 mg
Study: 11374852
Drug: Reduction in
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reduction in triglycerides in patients with baseline triglycerides >200 mg/dL (from Bezafibrate Infarction Prevention trial)
Study: 8795482
Drug: Coronary stenting
Normalized name: Glebionis coronaria whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coronary stenting with standardised anticoagulation regimen (intravenous heparin, oral vitamin K antagonist, 100 mg aspirin twice daily)
Study: 26945156
Drug: CHF6001 (inhaled
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHF6001 (inhaled PDE4 inhibitor)
Study: 26945156
Drug: Multiple ascending
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple ascending doses of CHF6001
Study: 647693
Drug: High-dose tamoxifen
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose tamoxifen
Study: 30060027
Drug: Lopinavir monotherapy
Normalized name: Lopinavir
DrugBank: Lopinavir (DB01601)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lopinavir monotherapy
Study: 23644384
Drug: Low-dose fentanyl
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose fentanyl plus placebo
Study: 3353076
Drug: methylprednisolone (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: methylprednisolone (1 g i.v. total dose)
Study: 31770574
Drug: Shenfu injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shenfu injection (SFI) in combination with epinephrine
Study: 31770574
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment with epinephrine alone
Study: 25980483
Drug: Atypical antipsychotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atypical antipsychotics (olanzapine 10-20 mg or risperidone 4-8 mg)
Study: 22718435
Drug: Doxycycline 100
Normalized name: doxycycline 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline 100 mg twice daily + Rifampin 300 mg daily
Study: 22718435
Drug: Doxycycline 100
Normalized name: doxycycline 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline 100 mg twice daily + Placebo-Rifampin daily
Study: 22718435
Drug: Rifampin 300
Normalized name: rifampin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampin 300 mg daily + Placebo-Doxycycline twice daily
Study: 22718435
Drug: Doxycycline or
Normalized name: doxycycline Oral Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline or Rifampin (alone or in combination)
Study: 16540931
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg oxandrolone
Study: 16540931
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg oxandrolone
Study: 19517600
Drug: Essential oils
Normalized name: essential oils
Approvals — FDA: no, EMA: no, PMDA: no
Description: Essential oils exposure; details on dosage and duration not specified.
Study: 17404515
Drug: New DTPw-HBV
Approvals — FDA: no, EMA: no, PMDA: no
Description: New DTPw-HBV vaccine
Study: 17404515
Drug: Licensed DTPw
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Licensed DTPw and HBV vaccines (given separately)
Study: 17404515
Drug: Licensed DTPw-HBV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Licensed DTPw-HBV combination (Tritanrix-HepB)
Study: 15205563
Drug: Bromocriptine (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromocriptine (2.5 mg daily for 3 months)
Study: 8485017
Drug: Amiloride (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiloride (5 and 20 mg)
Study: 8485017
Drug: Spironolactone (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spironolactone (25 and 100 mg)
Study: 359019
Drug: Hydrochlorothiazide (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide (100 mg)
Study: 31856379
Drug: Pecan nut
Normalized name: Pecan nut
DrugBank: Pecan (DB10555)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pecan nut group (PNG) - healthy diet plus 30 g day-1 of pecan nuts
Study: 31856379
Drug: Olive oil
Normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olive oil group (OOG) - healthy diet plus 30 mL day-1 of extra-virgin olive oil
Study: 15279528
Drug: Credible placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Credible placebo treatment (PL)
Study: 11515715
Drug: Crataegus extract
Normalized name: crataegus extract
DrugBank: Hawthorn leaf with flower (DB15839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crataegus extract WS 1442 (3 x 1 capsule)
Study: 2967477
Drug: Prednisolone methylsulfobenzoate
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisolone methylsulfobenzoate 30 mg
Study: 26887366
Drug: Minocycline quadruple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minocycline quadruple therapy
Study: 23511558
Drug: Preference for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preference for treatment decision
Study: 1729617
Drug: Calcium (1
Normalized name: hydroxyapatite 275 mg calcium (1,100 mg) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium (1 g of elemental calcium daily)
Study: 6390463
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg tiaprofenic acid per day, in 3 divided doses
Study: 6390463
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg indomethacin per day, in 3 divided doses
Study: 22066827
Drug: PPE (9
Approvals — FDA: no, EMA: no, PMDA: no
Description: PPE (9 capsules/day) as adjunctive therapy combined with HRT
Study: 22066827
Drug: Calcium (260
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium (260 mg/day) as adjunctive therapy combined with HRT
Study: 19588499
Drug: PicoGreen assay
Approvals — FDA: no, EMA: no, PMDA: no
Description: PicoGreen assay at cut-off point of 2.5 microg/ml
Study: 19588499
Drug: PicoGreen assay
Approvals — FDA: no, EMA: no, PMDA: no
Description: PicoGreen assay at cut-off point of 5.0 microg/ml
Study: 12808485
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of atorvastatin every other day
Study: 12808485
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of atorvastatin every day
Study: 12360164
Drug: Mean dose
Normalized name: OCTINOXATE 5 mg in 100 mL / AVOBENZONE 3 mg in 100 mL TOPICAL LOTION [Meaningful Beauty Cindy Crawford Maintenance 1 Daily Moisture SPF 8]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mean dose of atorvastatin in alternate-day group
Study: 12360164
Drug: Mean dose
Normalized name: OCTINOXATE 5 mg in 100 mL / AVOBENZONE 3 mg in 100 mL TOPICAL LOTION [Meaningful Beauty Cindy Crawford Maintenance 1 Daily Moisture SPF 8]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mean dose of atorvastatin in every-day group
Study: 10428529
Drug: Oestradiol valerate
Normalized name: Estradiol Valerate
DrugBank: Estradiol valerate (DB13956)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oestradiol valerate 2 mg daily for six months
Study: 30934166
Drug: Ertugliflozin (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ertugliflozin (5 mg and 15 mg)
Study: 17615904
Drug: Multi-vitamin syrup
Normalized name: Parasedge Multi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-vitamin syrup containing vitamin A (control group)
Study: 11992160
Drug: Tetravalent rhesus‐human
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetravalent rhesus‐human rotavirus vaccine (3 doses at 1st, 3rd, and 5th months of life)
Study: 11992160
Drug: Tetravalent rhesus‐human
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetravalent rhesus‐human rotavirus vaccine
Study: 1090892
Drug: Prednisone dosage
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisone dosage
Study: 26296539
Drug: Duloxetine 60
Normalized name: duloxetine 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine 60 mg once daily for 14 weeks
Study: 14506950
Drug: Vitamin K1
Normalized name: vitamin K1
DrugBank: Phylloquinone (DB01022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin K1 (1 mg/day) with mineral + vitamin D supplement (8 microg/day)
Study: 14506950
Drug: Mineral +
Normalized name: Mineral Oil
DrugBank: Mineral oil (DB11057)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mineral + vitamin D supplement (MD group)
Study: 11320158
Drug: Donepezil augmentation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Donepezil augmentation
Study: 2904053
Drug: Simvastatin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin (20 mg twice a day)
Study: 2904053
Drug: Cholestyramine (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholestyramine (8 g twice a day)
Study: 10368486
Drug: Sequential group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential group
Study: 25606700
Drug: Alirocumab 75
Normalized name: alirocumab 75 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alirocumab 75 mg subcutaneously every 2 weeks
Study: 25606700
Drug: Ezetimibe 10
Normalized name: ezetimibe 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ezetimibe 10 mg per os every day
Study: 11761026
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose of omeprazole (80 mg bolus + 8 mg/h for 3 days, i.e. 652 mg/72 h)
Study: 9259655
Drug: roxithromycin 150
Normalized name: roxithromycin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: roxithromycin 150 mg orally twice a day
Study: 9259655
Drug: placebo orally
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo orally twice a day
Study: 30341268
Drug: Mouthwash with
Normalized name: Sodium Fluoride 0.02% Oromucosal Solution [REMBRANDT WHITENING MOUTHWASH WITH FLUORIDE]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mouthwash with super-oxidized solution (SOS) Dermacyn® Wound Care
Study: 30341268
Drug: 0.2% chlorhexidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2% chlorhexidine gel (CHX)
Study: 18929360
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg of oral micronized progesterone (OMP) twice a day
Study: 15325864
Drug: Oral misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral misoprostol 50 microg four hourly to maximum of 5 doses
Study: 2978461
Drug: Nebulization treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulization treatment with terbutaline and ipratropium bromide (given separately with a 30‐minute interval or combined as single inhalation)